Cell Function and Viability in Glucose Polymer Peritoneal Dialysis Fluids

Objective To investigate the biocompatibility profile of a new peritoneal dialysis fluid containing glucose polymer (GPF). Design Viability and function of peripheral neutrophils (PMN) from healthy donors and cultured human peritoneal mesothelial cells were assessed in vitro after exposure to dialysis fluids. Phagocytosis, leukotriene B4 synthesis, and respiratory burst activation were measured following stimulation with serum-treated zymosan (STZ) or opsonized Staphylococcus epidermidis (S. epidermidis). Bacterial growth in the fluids was also investigated. In vivo pH equilibration of GPF and subsequent respiratory burst activation following incubation in spent dialysate were studied. Results For all the host defense parameters measured, commercial dialysis fluids (Dianeal; 1.36% and 3.86% glucose) and GPF (pH 5.2) were significantly more inhibitory than the control buffer (pH 7.3). Mesothelial cell viability was reduced by all the fluids tested irrespective of pH. Glucose polymer fluid was significantly more inhibitory than DianeaI 1.36% for STZ phagocytosis and respiratory burst activation. In contrast, it was less suppressive than DianeaI3.86% for L TB4 synthesis. For all parameters tested, except LTB4 generation, there was a marked effect of pH, with GPF being significantly more inhibitory at pH 5.2 than at pH 7.3. None of the fluids tested supported the growth of S. epidermidis, although the viable counts in GPF were significantly higher than in Dianeal. Fluid inhibition of PMN respiratory burst activation and cytotoxicity were reduced in a time-dependent manner following increasing dwell time in vivo. Conclusions GPF does not appear to be significantly different from Dianeal as far as host defense parameters are concerned. However, the cell viability and bacterial survival data suggest some possibly negative aspects of this fluid formation.

[1]  C. Holmes Biocompatibility of Peritoneal Dialysis Solutions , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[2]  N. Topley,et al.  Biocompatibility of Peritoneal Dialysis Fluids , 1992, The International journal of artificial organs.

[3]  E. Köttgen,et al.  Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. , 1992, American journal of nephrology.

[4]  M. Davies,et al.  In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  E. Köttgen,et al.  Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate. , 1991, Nephron.

[6]  N. Topley,et al.  Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  H. Verbrugh,et al.  Host defence in CAPD treatment: the effect of the dialysate on cell function. , 1990, Contributions to Nephrology.

[8]  E. Stylianou,et al.  Isolation, culture and characterization of human peritoneal mesothelial cells. , 1990, Kidney international.

[9]  B. Spur,et al.  Differential augmentation by recombinant human tumor necrosis factor-alpha of neutrophil responses to particulate zymosan and glucan. , 1990, Journal of immunology.

[10]  M. A. Rahman,et al.  Effects of bicarbonate-containing versus lactate-containing peritoneal dialysis solutions on superoxide production by human neutrophils. , 2008, Artificial organs.

[11]  H. Verbrugh,et al.  Cytotoxic Effects of Commercial Continuous Ambulatory Peritoneal Dialysis (CAPD) Fluids and of Bacterial Exoproducts on Human Mesothelial Cells in Vitro , 1989, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[12]  J. Cook,et al.  Viability measurements in mammalian cell systems. , 1989, Analytical biochemistry.

[13]  D. Oreopoulos,et al.  The physiology of peritoneal dialysis. , 1989, American journal of nephrology.

[14]  D. Lloyd,et al.  The effect of dialysate on peritoneal phagocyte oxidative metabolism. , 1988, Kidney international.

[15]  R. Beelen,et al.  Peritoneal Macrophages in Short Dwell Time Effluent Show Diminished Phagocytosis , 1988 .

[16]  R. Gokal,et al.  ULTRAFILTRATION WITH AN ISOSMOTIC SOLUTION DURING LONG PERITONEAL DIALYSIS EXCHANGES , 1987, The Lancet.

[17]  J. Watts,et al.  Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions , 1986, Journal of clinical microbiology.

[18]  C. Bartell,et al.  In vitro study of bacterial growth in continuous ambulatory peritoneal dialysis fluids , 1986, Journal of clinical microbiology.

[19]  K. Nolph,et al.  Osmotic agents and ultrafiltration in peritoneal dialysis. , 1986, Nephron.

[20]  D. Lloyd,et al.  Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. , 1986, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  B. Gallimore,et al.  Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice. , 1986, Nephron.

[22]  K. Alberti,et al.  Short-term studies on the use of glycerol as an osmotic agent in continuous ambulatory peritoneal dialysis (CAPD). , 1984, Clinical science.

[23]  C. Korzeniewski,et al.  An enzyme-release assay for natural cytotoxicity. , 1983, Journal of immunological methods.

[24]  J. Harrison,et al.  Effective Use of Amino Acid Dialysate over four Weeks in CAPD Patients , 1983, Transactions - American Society for Artificial Internal Organs.

[25]  A. Duwe,et al.  Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro , 1981, Infection and immunity.